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France and 6) National Centre for Transplantation, Infectious and Tropical Diseases Department, University of Insubria, Varese, ItalyAbstractThere is limited clinical evidence on the utility of the monitoring of Epstein–Barr virus (EBV) DNAemia in the pre-emptive management of
post-transplant lymphoproliferative disease (PTLD) in solid organ transplant (SOT) recipients. We investigated current preventive measures
against EBV-related PTLD through a web-based questionnaire sent to 669 SOT programmes in 35 European countries. This study was
performed on behalf of the ESGICH study group from the European Society of Clinical Microbiology and Infectious Diseases. A total of
71 SOT programmes from 15 European countries participated in the study. EBV serostatus of the recipient is routinely obtained in 69/71
centres (97%) and 64 (90%) have access to EBV DNAemia assays. EBV monitoring is routinely used in 85.9% of the programmes and
77.4% reported performing pre-emptive treatment for patients with signiﬁcant EBV DNAemia levels. Pre-emptive treatment for EBV
DNAemia included reduction of immunosuppression in 50.9%, switch to mammalian target of rapamycin inhibitors in 30.9%, and use of
rituximab in 14.5% of programmes. Imaging by whole-body 18-ﬂuoro-deoxyglucose positron emission tomography (FDG-PET) is used in
60.9% of centres to rule out PTLD and complemented computer tomography is used in 50%. In 10.9% of centres, FDG-PET is included
in the ﬁrst-line diagnostic workup in patients with high-risk EBV DNAemia. Despite the lack of deﬁnitive evidence, EBV load
measurements are frequently used in Europe to guide diagnostic workup and pre-emptive reduction of immunosuppression. We need
prospective and controlled studies to deﬁne the impact of EBV monitoring in reducing the risk of PTLD in SOT recipients.
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p://dx.doi.org/10.1016/j.cmi.2015.02.002IntroductionPost-transplant lymphoproliferative disorder (PTLD) is a feared
complication after solid organ transplantation (SOT), occurringious Diseases. Published by Elsevier Ltd. All rights reserved
CMI San-Juan et al. EBV-related post-transplant lymphoproliferative disease 604.e2in 1–30% of recipients [1–3] with an overall mortality that may
be as high as 50% [4,5].
Most cases of PTLD have been associated with Epstein–Barr
virus (EBV), mostly in patients undergoing primary EBV infec-
tion after transplantation [6]. Whereas treatment of advanced
PTLD typically requires chemotherapy, early polyclonal or
oligoclonal stages may initially respond to reduced immuno-
suppression combined with rituximab therapy and therefore
the possibility of pre-emptive treatment has received consid-
erable attention. In haematopoietic stem cell transplant re-
cipients surveillance of EBV DNAemia by quantitative nucleic
acid testing (QNAT) has been used to identify patients at risk
for PTLD development [7–9]. However, the clinical evidence
supporting EBV DNA monitoring in SOT recipients is limited
[10] and, although major advances have been made in the
incorporation of QNAT-based EBV detection techniques in
clinical microbiology laboratories, there is no consensus on
optimal techniques, the best monitoring timing, or the most
accurate cut-offs in viral load indicating high risk for PTLD
development [11–13]. The objective of the present study was
to evaluate the current practices with respect to EBV-
associated PTLD in SOT recipients in Europe through a sur-
vey conducted on behalf of the ESCMID Study Group of
Infection in Compromised Hosts (ESGICH) and directed to all
the European SOT centres.Materials and methodsThe study design was a questionnaire-based cross-sectional
survey performed on behalf of the ESGICH from the ESCMID.
We contacted the different potentially active SOT programmes
(including kidney, pancreas/kidney–pancreas, liver, heart, lung
and intestinal transplants) through registries accessed in web-
sites from different governmental or scientiﬁc organizations,
depicted in the Supporting information (Appendix S1). To ﬁnd
the e-mail address of each SOT programme representative,
apart from the contact e-mails provided in the different regis-
tries we also searched those included in PubMed published
studies performed in these centres from 2008 to 2013. More e-
mail contacts of virologists and Transplant Infectious Diseases
(TID) specialists eventually involved in the management of
PTLD were requested from these initially selected transplant
centres. The survey was carried out between 1 and 30 June
2013. An e-mailed invitation and a weekly reminder with a
summary of the project and a personal link to an internet
questionnaire service provider (https://es.surveymonkey.com/)
was sent to all the representatives. The basal module of the
survey consisted of a total of 26 ‘hot topics’ questions related
to the prevention of EBV-related PTLD that had beenClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inpreviously proposed and reviewed through a panel of experts
of ESGICH (Supporting information, Appendix S2). A comple-
mentary survey module was designed for virologists that
included some more speciﬁc questions with respect to the basal
module (Supporting information, Appendix S3).
We arbitrarily deﬁned high-risk EBV DNAemia as one or
more of the following: (1) high-level DNAemia (above the 90th
centile of values obtained in the laboratory) (2) increasing
DNAemia (more than tenfold or >1 log10 copies (cp)/mL in
two consecutive determinations), and (3) persistent DNAemia
(persistence of EBV DNAemia in at least two consecutive de-
terminations separated by at least 3 months).
The study was approved by the speciﬁc scientiﬁc Committee
of the European Society of Clinical Microbiology and Infectious
Diseases. Requests for authorization by the ethics committees
of each centre were not considered necessary because this was
a survey that simply collected the opinions of transplant phy-
sicians, and it did not involve approaching patients directly or
seeking any patient-speciﬁc data.Statistical methodsA database including all the responses of the participants was
provided by the internet questionnaire service for further
analysis. Continuous variables were expressed as the mean for
those with a normal distribution, and as the median (mostly for
those with a skewed distribution). Discrete variables were
expressed as percentages. Student’s unpaired t-test was used to
compare continuous variables, the Mann–Whitney U-test to
compare continuous variables with non-normal distribution,
and the chi-square or Fisher exact test to compare pro-
portions. All statistical tests were two-tailed and the threshold
of statistical signiﬁcance was p < 0.05. The statistical software
SPSS (SPSS 15.0, Inc., Chicago, IL, USA) was used to perform
the calculations of the different analyses.ResultsAn invitation for participating in the survey was sent by e-mail
to 669 physicians representing 669 SOT groups from 35 Eu-
ropean countries.
A total of 71 transplant physicians (TP) representatives of
SOT groups from 15 European countries ﬁnally participated in
the study which supposed a global participation of 10.5%. As is
shown in Table 1, all the types of SOT were represented in the
survey and the percentage of participation varied from 24.5% in
lung transplant to 4% in pancreas transplant programmes. Spain
and Italy were the most represented countries (participation offectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 604.e1–604.e9
TABLE 1. Participation in the survey of European solid organ
transplant groups
Survey
proposal
Accepted
participation % participation
Per type of transplant group
Lung transplant 53 13 24.5%
Bowel transplant 31 4 12.9%
Liver transplant 107 13 12.1%
Renal transplant 285 30 10.5%
Heart transplant 96 7 7.3%
Pancreas transplant 97 4 4.1%
Per country of origin
Slovenia 2 2 100%
Spain 81 20 24.7%
Italy 120 23 19.2%
Czech Republic 10 2 20.0%
Switzerland 17 3 17.6%
France 92 7 7.6%
Belgium 29 2 6.9%
Germany 117 4 3.4%
United Kingdom 76 2 2.6%
Other 125 6 4.8%
TOTAL 669 71 10.5%
604.e3 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMI24.7% and 19.2%, respectively). Additionally, from the total of
47 TID consultants and 28 virologists contacted, through
responding transplant physicians, 17 (36.2%) and 13 (46.4%)
participated, respectively.Characteristics of participating SOT centresAs shown in Table 2, the majority of the participants were
highly experienced adult transplant groups (nearly 90% with
transplant programmes with experience over 10 years) and
with a high transplant activity. EBV serostatus of the recipientTABLE 2. Characteristics of the 71 European SOT
programmes participating in the survey
Type of transplant, n (%)
Kidney 30 (42.3)
Liver 13 (18.3)
Heart 7 (9.9)
Lung 13 (18.3)
Pancreas 4 (5.6)
Small bowel 4 (5.6)
Paediatric transplant, n (%) 9 (13.2)
Experience of the SOT programme, n (%)
>20 years 46 (64.8)
16–20 years 9 (12.7)
11–15 years 7 (9.9)
5–10 years 8 (11.3)
<5 years 1 (1.4)
Number of transplants performed in 2012,
median (range)
Kidney 62 (10–199)
Liver 40 (16–87)
Heart 18 (11–33)
Lung 17 (2–115)
Pancreas 3 (2–12)
Small bowel 47 (4–88)
Routine determination of EBV serostatus, n (%)
Recipient 69 (97.2)
Donor 54 (76.1)
EBV DNAemia determination available at the
Transplant centre, n (%)
64 (90.1)
Abbreviations: EBV, Epstein–Barr virus; SOT, solid organ transplantation.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectwas routinely recorded in 69 centres (97%) and 64 (91%) had
quantitative EBV DNAemia measurements in place.Preventive measures guided by clinical risk
factorsAs shown in Table 3, EBV serological mismatch is perceived as
the major risk factor for PTLD development in 71.8% of
surveyed TP, followed by the use of lymphocyte-depleting
treatments (15.5%). Thirty-eight TP reported the use of pre-
ventive measures in patients with clinical high-risk factors,
irrespective of EBV DNAemia monitoring, including the use of
valganciclovir in 11.3% of transplant programmes, and the
change of immunosuppression from calcineurin inhibitors to
mammalian target of rapamycin inhibitors (m-TORi) in 12.7%
of the transplant groups. Compared with TP, only 11.8 of
surveyed TID specialists supported implementation of such
measures (p 0.08) exclusively through the use of
valganciclovir.Preventive measures against PTLD based in
EBV-DNAemia monitoringAs shown in Table 4, 55 of the 64 centres (85.9%) with
QNAT techniques in place performed some kind of EBV
surveillance. Although nearly 40% reported performing EBV
load surveillance in patients with clinical suspicion of PTLD,
34.4% of the centres perform EBV load surveillance in all SOT
recipients: 16.6% and 18.2% in liver and heart transplant, 33%
and 38% in pancreas and renal transplant, and 45.4% and 50%
in lung and intestinal transplant, respectively. TID specialists
were more likely to restrict EBV surveillance to selected high-
risk patients than TP (43.8% versus 12.5%, p 0.01), and only
12.5% of TID consultants favour the use of universal EBV
surveillance.
The majority of TP (77.4%) use preventive measures in pa-
tients with high-risk EBV DNAemia, such as the reduction of
immunosuppression (50.9%), and the conversion to m-TORi
(30.9%). Up to 14.5% afﬁrmed that they had used rituximab for
this indication and 7.3% even indicated the use of immune-
adoptive T-cell therapy. In any case, inclusion of such preven-
tive measures in transplant procedure institutional protocols
was less reported, only in 18.2% of the centres.
Indication of a whole-body computed tomography (CT)
prompted exclusively by high-risk EBV DNAemia was reported
in 7.8% of the centres overall, and it was recommended by
31.3% of the TID representatives (p 0.03).ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 604.e1–604.e9
TABLE 4. Preventive measures against PTLD based in EBV DNAemia monitoring
Transplant
physicians
Infectious
disease
consultants p-valuea
Any kind of monitoring of EBV DNAemia in SOT?, n (%) n = 64 n = 16
U/NA 2 (3.1) 0
No, never. 7 (10.9) 0 0.37
Only in patients with suspicion of established PTLD 25 (39.1) 7 (43.8)
Only in SOT at high risk for PTLD 8 (12.5) 7 (43.8) 0.01
Yes, in all SOT recipients. 22 (34.4) 2 (12.5) 0.16
Any kind of EBV DNAemia monitoring 55 (85.9) 16 (100) 0.22
Experience on preventive measures directed by EBV DNAemia determination, n (%) n = 55b n = 16
At least one preventive measure 31 (77.4) 9 (56.3) 0.18
Acyclovir/Valacyclovir 5 (9.1) 1 (5.9)
Ganciclovir/valganciclovir 7 (12.7) 1 (5.9)
Reduction of IS 28 (50.9) 5 (29.4) 0.22
Change IS to m-TORi 17 (30.9) 6 (35.3)
Rituximab 8 (14.5) 2 (11.8)
Immuno-adoptive therapy 4 (7.3) 1 (5.9)
Protocolized preventive measures directed by EBV DNAemia determination, n (%) n = 55b n = 16
At least one preventive measure 10 (18.2) 1 (6.3) 0.44
Acyclovir/Valacyclovir 1 (1.8) 0
Ganciclovir/valganciclovir 4 (7.3) 0
Reduction of IS 7 (12.7) 0
Change IS to m-TORi 4 (7.3) 0
Rituximab 3 (5.5) 0
Immuno-adoptive therapy 1 (1.8) 0
Other 0 1 (6.3)
Total body CT for PTLD evaluation in patients with high-risk EBV DNAemia?, n (%) n = 64 n = 16
U/NA 6 (9.3) 0
No 9 (14.1) 0 0.2
Only when clinical and/or analytical data suggestive of PTLD 44 (68.7) 11 (68.8)
Yes, in the majority of patients with high-risk EBV DNAemia 5 (7.8) 5 (31.3) 0.03
Use of FDG-PET whole-body for PTLD evaluation in patients with high-risk EBV DNAemia?, n (%) n = 64 n = 16
U/NA 6 (9.4) 0
It is protocolized for PTLD evaluation in patients with high risk of PTLD 7 (10.9) 2 (12.5)
Sometimes, complementary to CT 32 (50) 12 (75) 0.13
We have no experience in this indication. 19 (29.7) 2 (12.5) 0.28
Biopsy of the graft for PTLD evaluation in patients with high risk EBV DNAemia?: n (%) n = 64 n = 16
U/NA 6 (9.4) 0
No 16 (25) 3 (18.8)
Only when clinical data suggestive of PTLD 39 (61) 13 (81.3) 0.22
Yes, in the majority of patients with high risk EBV DNAemia 3 (4.7) 0
Lymphatic node biopsy for PTLD evaluation in patients with high-risk EBV DNAemia?: n (%) n = 64 n = 16
U/NA 6 (9.4) 0
No 12 (18.8) 0 0.14
Only when clinical/radiological/analytical data suggestive of PTLD 42 (65.6) 16 (100) 0.01
Yes, in the majority of patients with high risk EBV DNAemia 4 (6.3) 0
Abbreviations: CT, computed tomography; EBV, Epstein–Barr virus; FDG-PET, 18-ﬂuoro-deoxyglucose positron emission tomography; IS, immunosuppression; m-TORi,
mammalian target of rapamycin inhibitors; PTLD, post-transplant lymphoproliferative disease; SOT, solid organ transplantation; U/NA, Unknown/No answer.
aOnly p values <0.5 are shown.
bSubgroup of centres performing EBV DNAemia monitoring.
TABLE 3. Prevention of PTLD independently of EBV DNAemia determination
Transplant physicians
n = 71
Infectious disease
consultants n [ 16 p valuea
Which is the major clinical risk factor for PTLD?, n (%)
Use of lymphocyte-depleting treatments 11 (15.5) 1 (5.9)
Seronegative EBV recipient with a seropositive
EBV donor
51 (71.8) 15 (88.2)
Type of transplanted organ 3 (4.2) 0
No speciﬁc risk factors have been reported 6 (8.5) 1 (5.9)
Have you used preventive measures in patients with high clinical risk factors?, n (%)
At least one preventive measure 27 (38) 2 (11.8) 0.08
Oral acyclovir 2 (2.8) 0
Oral valacyclovir 4 (5.6) 0
Intravenous ganciclovir 2 (2.8) 0
Oral valgancyclovir 8 (11.3) 2 (11.8)
Change immunosuppression to mammalian target
of rapamycin inhibitors
9 (12.7) 0 0.2
Abbreviations: EBV, Epstein–Barr virus; PTLD, post-transplant lymphoproliferative disease.
aOnly p values <0.5 are shown.
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604.e5 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMIExperience of whole-body 18-ﬂuoro-deoxyglucose positron
emission tomography (FDG-PET) as a diagnostic tool for
discard PTLD was reported in 60.9% of surveyed centres (in
50% complementary to CT) and it was included in protocols of
diagnostic workup in patients with high-risk EBV DNAemia in
10.9% of them. However, one-third of the transplant centres
did not report any experience with FDG-PET. Invasive diag-
nostic measures such as allograft biopsy or lymphatic node bi-
opsy were generally performed only in patients with clinical
manifestations compatible with PTLD (61% and 65.6%,
respectively).
To test the effect of the characteristics of the different
centres in the answers regarding preventive measures against
PTLD based in EBV DNAemia monitoring we analysed the
results stratiﬁed by transplant activity in the previous year (40
centres with a number of transplants below the 50th centile and
31 above this value) and we did not ﬁnd any statistically sig-
niﬁcant differences among both groups.
We also compared the results between the nine centres for
paediatric transplants and 62 adult transplant programmes.
Universal monitoring of EBV DNAemia was reported signiﬁ-
cantly more frequently in paediatric transplant than in adult
transplant programmes (78% versus 27%; p 0.01) as were the
use of preventive measures guided by EBV DNAemia (89%
versus 44.7%; p 0.02). Interestingly, the report of the use of
rituximab as pre-emptive therapy was also signiﬁcantly more
frequent in paediatric transplant programmes (62.5% versus
6.5%; p < 0.0001).TABLE 5. PCR assay for EBV DNAemia monitoring
Type of PCR technique, n (%)
Unknown
Real-Time PCR commercial
Real-Time PCR laboratory-developed
Type of clinical sample for PCR determination, n (%)
Unknown
Plasma
Separated mononuclear cells
Whole blood
Values of EBV DNAemia considered as high DNAemia?, n (%)
U/NA
More than 100 cp/mL
More than 1000 cp/mL
More than 1500 cp/mL
More than 5000 cp/mL
More than 10 000 cp/mL
EBV PCR target included in the PCR technique, n (%)
Unknown
BALF5
BamHI-W
BNRF1 P 143
BXLF1
EBNA-1
Others
Awareness of WHO expert Committee on standardizationb, n (%)
No
I am aware but I have not accessed the contents
I have accessed the contents of the document
aSubgroup of centres performing EBV DNAemia monitoring.
bFirst WHO International Standard for Epstein–Barr Virus (EBV) for Nucleic Acid Ampliﬁc
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectEBV DNAemia determinationWe ﬁnally surveyed some general aspects of the QNAT tech-
niques used for determining EVB DNAemia loads com-
plemented by some more speciﬁc issues in the speciﬁc
formularies directed to transplant virologists (Table 5). Com-
mercial QNAT were the most frequently used assays, but at
least 35.7% of the clinical virologists reported the use of
laboratory-developed tests. Whole blood was the preferred
clinical specimen in the majority of centres (45.5% reported by
TP, 31.3% by TID and 57.1% by clinical virologists), and plasma
specimens were used in a signiﬁcant proportion of centres
(29.1% TP, 50% TID consultants, and 35.7% clinical virologists).
We assumed that there is not a speciﬁc cut-off point and we
asked which values were assumed to reﬂect ‘high’ DNAemia
(deﬁned in the formulary as those above the 90th centile).
Interestingly, the values of DNAemia considered to be high
were variable and depended on the PCR technique used. TP
tended to consider lower EBV loads as ‘high-risk’ DNAemia
(34.5% >1000 cp/mL and 12.7% >100 cp/mL) than did TID
(37.5% >5000 cp/mL) or virologists (42.9% >10 000 cp/mL). It
is noteworthy that virologists reported a high variability in the
targets included in the PCR technique, and about 28.5% were
not aware of this detailed aspect of the test. Further, 28.6% of
virologists were unaware of the WHO experts committee
recommendations published in 2011 [14] and only 57.1% had
accessed the contents of the document.Transplant physicians ID consultants Virologist
n = 55a n = 16 n = 14
13 (23.6) 1 (6.3) 0
38 (69.1) 7 (43.8) 9 (64.3)
4 (7.3) 8 (50) 5 (35.7)
n = 55a n = 16 n = 14
11 (20) 3 (18.8) 0
16 (29.1) 8 (50) 5 (35.7)
3 (5.5) 0 1 (7.1)
25 (45.5) 5 (31.3) 8 (57.1)
n = 55a n = 16 n = 14
5 (9.1) 3 (18.8) 1 (7.1)
7 (12.7) 1 (6.3) 1 (7.1)
19 (34.5) 3 (18.8) 2 (14.3)
4 (7.3) 2 (12.5) 1 (7.1)
11 (20) 6 (37.5) 3 (21.4)
9 (16.4) 1 (6.3) 6 (42.9)
NA NA n = 14
— — 4 (28.5)
— — 1 (7.1)
— — 1 (7.1)
— — 3 (21.4)
— — 3 (21.4)
— — 1 (7.1)
— — 1 (7.1)
NA NA n = 14
— — 4 (28.6)
— — 2 (14.3)
— — 8 (57.1)
ation Technology (NAT)-Based Assays [14].
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 604.e1–604.e9
CMI San-Juan et al. EBV-related post-transplant lymphoproliferative disease 604.e6DiscussionThe results of this pan-European survey offer a current picture
of the attitude of the different groups of TP towards prevention
of EBV-related PTLD. The majority of transplant group repre-
sentatives were aware of the importance of EBV in the devel-
opment of PTLD and they veriﬁed the widely accepted role of
serological screening of recipient and donor [3,15–17]. Up to
40% of the groups acknowledged that some preventive measures
are performed in high-risk patients, mostly represented by
seronegative recipients from seropositive EBV donors. How-
ever, this position was extended by some to patients treated
with lymphocyte-depleting treatments, a condition that has also
been related with an added risk in some studies [5,15,18–20].
The most frequently reported preventive measures applied
in high-risk patients were the use of valgancyclovir and the
prescription of m-TORi as part of the immunosuppressive
regimen. Although there is some previous experience sug-
gesting some protective effect of anti-CMV drugs against the
development of PTLD [21,22], the evidence supporting the use
of (val-)ganciclovir in EBV-high-risk SOT is weak [10].
Our survey indicates that more than 85% of the centres
apply some kind of EBV DNAemia monitoring in their patients
(mostly lung and intestinal transplant recipients), and approxi-
mately one-third of participants report monitoring all SOT
recipients. TID specialists appeared to be more restrictive
regarding the use of EBV surveillance, applying this only to high-
risk patients, as is currently recommended [10].
The information provided by transplant virologists points out
the lack of standardization of EBV PCR assays. Whole blood
samples were preferred in themajority of laboratories, but a great
diversitywas observed according to the viral sequence targeted by
theQNATassay, and considerable variability existed in the trigger
point used to identify a patient at high risk that warrants pre-
emptive or diagnostic strategies. On the other hand, a high vari-
ability regarding the time-points of EBV surveillancewasobserved.
These basic issues, like which sample should be tested [23] or the
timing of monitoring, have not been clearly determined [24–27]
although measuring EBV loads in whole blood or white blood
cells seems to be more sensitive [28]. Also, the identiﬁcation of a
clinical or diagnostic threshold remains obscure [24].
Given the lack of consensus on a ﬁxed numeric threshold of
EBV load for diagnosis or for pre-emptive intervention [24],
some authors have suggested that the kinetics of EBV load may
be the most informative parameter to deﬁne the risk of
developing PTLD [25,29]. In that regard, the availability of a
WHO International Standard for EBV for Nucleic Acid Tech-
niques [14,26,30] should help to solve problems of inter-
laboratory standardization [13].Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InDespite the limitations discussed above, almost 80% of trans-
plant centres reported some kind of experience on the application
of preventive measures directed by EBV DNAemia. Reduction of
immunosuppression was the most frequently used (50% of the
transplant programmes). The published experience on EBV pre-
emptive strategies in the SOT setting invariably includes the
reduction of immunosuppression, either as the sole strategy
[31,32], or as a combination strategy with antiviral agents, immu-
noglobulins [33], or rituximab [34,35]; reduction of immunosup-
pression being the most clearly recommended measure [10].
Another frequently used pre-emptive measure was the
switch from calcineurin inhibitors to m-TORi, which was re-
ported in 30% of the centres. Although some case reports of
encouraging responses have been communicated concerning
patients with PTLD after a conversion from calcineurin in-
hibitors to mTORi [36], the current strength for recom-
mending this pre-emptive strategy is weak [10,37].
The use of antivirals in patients with high-risk EBV DNAemia
was reported in 22% of the institutions, valganciclovir being the
drug most frequently prescribed. Unlike what happens in some
SOT paediatric patients who are seronegative for EBV [38,39],
there is no evidence that antiviral agents are helpful in EBV-
seropositive SOT adult recipients with high EBV loads. How-
ever, some experts would consider the use of these antivirals as
an adjunctive measure to the reduction of immunosuppression
in selected patients [10].
Interestingly, pre-emptive therapy with rituximab was re-
ported globally in 14.5% of the transplant programmes, and in
more than 60% of paediatric transplant centres. Although some
favourable experience of its use has been reported in SOT
[34,35] the limited supporting evidence plus potentially severe
adverse events had relegated this strategy to be a ﬁnal step— to
be considered in some patients with persistent and/or increasing
EBV DNAemia in spite of reduction of immunosuppression [10].
An important ﬁrst step to managing SOT recipients with
high-risk EBV DNAemia is to reasonably rule out PTLD [10].
The results of the survey conﬁrm that whole-body FDG-PET is
frequently used for the workup of patients at risk for PTLD.
More aggressive diagnostic techniques, such as biopsy of either
the graft or the lymphatic nodes, are usually reserved for pa-
tients with clinical data suggestive of PTLD and only 4–6% of
surveyed centres report its indication in patients with asymp-
tomatic high-risk EBV DNAemia.
Apart from innate potential biases common to all online
physician questionnaires, the major limitation of the present
study was the low global response; the search for potentially
active SOT programmes was based in web-based registries that
could not be adequately updated and, therefore, the real
number of active SOT programmes is presumably lower so that
an under-estimation of the rate of survey response is probable.fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 604.e1–604.e9
604.e7 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMISome important European countries, such as Germany, France
and United Kingdom, were under-represented in the re-
sponders so the survey does not accurately represent the en-
tirety of the centres performing SOT in northern Europe. On
the other hand, it could constitute a signiﬁcant bias because the
centres that responded were the most sensitive to this issue
and may not represent the usual practice in most other centres.
In summary, in view of the results of the present survey, pre-
emptive management of EBV-related PTLD is an issue of concern
for European physicians involved in SOT and the availability of
EBV DNAemia assays for monitoring is currently a reality in the
majority of SOT programmes. In spite of the lack of scientiﬁc
supporting evidence, pre-emptive therapy is being performed in
patients with high-risk EBV DNAemia in Europe, mostly through
reduction of immunosuppression but also through the switch to
m-TORi, the use of antiviral agents and even the administration
of rituximab in some situations. More studies are needed
focused on the accurate establishment of the population at risk
for PTLD and the efﬁciency of EBV-monitoring-based pre-
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